We expect that using the proposed pipeline will expand the routine use of tau PET, which will support tracking biomarkers associated with cognitive decline that precedes symptomatic progression of AD (2), predicting the trajectory of AD-related cognitive decline (1), and identifying the window of therapeutic intervention for improving prognosis (6). This evidence concerns the gene MAPT and Alzheimer disease.